STRIBILD
Peakelvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
NDAORALTABLET
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Data completeness
6/8 — Strong
STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) by Gilead Sciences is hiv integrase inhibitors [moa]. Approved for human immunodeficiency virus integrase strand transfer inhibitor [epc]. First approved in 2012.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STRIBILD is a once-daily oral fixed-dose combination tablet containing elvitegravir (an HIV integrase strand transfer inhibitor), cobicistat (a pharmacokinetic booster), emtricitabine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. It works by inhibiting HIV integrase, an enzyme required for viral replication, while the other components provide complementary antiretroviral activity. This combination simplifies HIV therapy by delivering four active agents in a single tablet.
$28MPart D
PeakStable
6.4 years to LOESTRIBILD is at peak maturity with modest Medicare Part D claims; the brand team is likely focused on maintaining market position as newer agents gain traction.
Mechanism of Action
HIV Integrase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Clinical Trials (11)
Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Started Feb 2015
21 enrolled
HIVAIDSSleep Disorders
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
Started Dec 2014
72 enrolled
HIV-1 Infection
STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)
Started Nov 2014
30 enrolled
HIVIllicit Drug User
Sleep and Cognition After Atripla to Stribild Switch
Started Sep 2014
30 enrolled
HIV
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Started Sep 2014
30 enrolled
HIV-2 Infection
Worked on STRIBILD at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.